Current issues in the identification and treatment of metabolically healthy but obese individuals

被引:36
作者
Plourde, G. [1 ,2 ]
Karelis, A. D. [3 ]
机构
[1] Hlth Canada, Ctr Evaluat Radiopharmaceut & Biotherapeut, Drug Safety Unit, Biol & Genet Therapies Directorate,Directors Off, Ottawa, ON K1A OK9, Canada
[2] Univ Ottawa, Fac Hlth Sci, Sch Human Kinet, Ottawa, ON, Canada
[3] Univ Quebec, Dept Kinanthropol, Montreal, PQ H3C 3P8, Canada
关键词
Metabolically healthy obese; Metabolically unhealthy obese; Treatment; Clinical practice; BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; WEIGHT-LOSS; ALL-CAUSE; RISK; PHENOTYPE; INFLAMMATION; DEFINITION; PREVALENCE; OVERWEIGHT;
D O I
10.1016/j.numecd.2013.12.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A unique subset of obese individuals who appear to be protected from the development of metabolic disturbances has been identified in the medical literature and is termed metabolically healthy but obese (MHO). Part of the issue is that there are no clear accepted criteria on the definition of MHO and the biological mechanisms to explain this phenotype are still unknown which render findings and/or conclusions difficult to interpret and making the application of this concept difficult in clinical practice. With the current definitions, the true prevalence of the MHO phenotype in the general population varies widely from approximately 3-57% of obese adults. In several prospective studies, the MHO individual has been associated with a similar risk of developing type 2 diabetes, cardiovascular disease and mortality when compared to healthy normal weight subjects; however, there is evidence to refute this concept. Furthermore, the current evidence cannot confirm that MHO subjects are permanently protected from the risk of developing metabolic disturbances associated with obesity. Currently, no standard practice guidelines for the treatment of MHO can be proposed, however, a regular surveillance of the waist circumference and cardio-metabolic risk factors such as elevated triglycerides, glycaemia, HOMA, C-reactive protein and low HDL, as well as the prevention of any further weight gain seem to represent the most prudent and sound attitude in the management of MHO subjects. (C) 2014 Elsevier B. V. All rights reserved.
引用
收藏
页码:455 / 459
页数:5
相关论文
共 34 条
[31]   Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women [J].
Shin, M-J ;
Hyun, Y. J. ;
Kim, O. Y. ;
Kim, J. Y. ;
Jang, Y. ;
Lee, J. H. .
INTERNATIONAL JOURNAL OF OBESITY, 2006, 30 (10) :1529-1534
[32]   Metabolic fitness in active reduced-obese individuals [J].
Tremblay, A ;
Doucet, E ;
Imbeault, P ;
Mauriège, P ;
Després, JP ;
Richard, D .
OBESITY RESEARCH, 1999, 7 (06) :556-563
[33]   Metabolically healthy obesity: different prevalences using different criteria [J].
Velho, S. ;
Paccaud, F. ;
Waeber, G. ;
Vollenweider, P. ;
Marques-Vidal, P. .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2010, 64 (10) :1043-1051
[34]   The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering - Prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004) [J].
Wildman, Rachel P. ;
Muntner, Paul ;
Reynolds, Kristi ;
McGinn, Aileen P. ;
Rajpathak, Swapnil ;
Wylie-Rosett, Judith ;
Sowers, MaryFran R. .
ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (15) :1617-1624